Isis and GlaxoSmithKline eye Phase III with a rare disease drug

Damian Garde

and partner Pharmaceuticals are plotting a pivotal trial in the TTR amyloid cardiomyopathy, an inherited that impairs the heart muscle.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS